Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue and profit increased due to expanding demand, particularly for generative AI-related products, the effects of the acquisition of ams-OSRAM AG's light-source business, the weaker yen, an improved product mix, structural reforms, and lower selling, general and administrative expenses.
No applicable items
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥103,538 million (YoY +27.2%) |
| Operating profit | ¥9,788 million (YoY +143.8%) |
| Ordinary income | ¥9,674 million (YoY +92.2%) |
| Profit attributable to owners of the parent | ¥5,367 million |
| Total assets | ¥366,905 million |
| Net assets | ¥219,519 million |
| Cash flows from operating activities | ¥13,022 million |
| Cash flows from investing activities | ¥2,683 million |
| Cash flows from financing activities | ¥-16,359 million |
| Cash and cash equivalents at end of period | ¥70,642 million |
| Segment revenue | Industrial Process business ¥46,369 million (YoY +34.7%), Visual Imaging business ¥46,563 million (YoY +22.3%), Life Science Business ¥3,628 million (YoY +10.4%), Photonics Solution business ¥6,388 million (YoY +28.4%), Other business ¥600 million (YoY -10.0%) |
| Segment profit | Industrial Process business ¥5,689 million (YoY +177.8%), Visual Imaging business ¥2,278 million (YoY +26.2%), Life Science Business ¥395 million (YoY +133.5%), Photonics Solution business ¥1,404 million, Other business ¥71 million |
| Depreciation and amortization | ¥4,589 million |
| Impairment loss | ¥918 million; target assets: Not disclosed |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of fixed assets ¥12 million, Gain on sales of investment securities ¥208 million / Extraordinary loss Loss on disposal of fixed assets ¥107 million, Loss on sale of non-current assets ¥30 million, Impairment loss ¥918 million, Loss on valuation of investment securities ¥131 million |
| Disclosure regarding the going concern assumption | No applicable items |
| Factors Behind Changes in Business Performance | Revenue and profit increased due to expanding demand, particularly for generative AI-related products, the effects of the acquisition of ams-OSRAM AG's light-source business, the weaker yen, an improved product mix, structural reforms, and lower selling, general and administrative expenses. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was due to expanding demand for semiconductors and electronic devices, particularly those related to generative AI, the effects of the acquisition of ams-OSRAM AG's light-source business, the weaker yen, an improved product mix, and the effects of structural reforms and reductions in selling, general and administrative expenses.